iTeos Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】iTeos Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C11170)・商品コード:DATA904C11170
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:29
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
iTeos Therapeutics SA (iTeos) is a biotechnology company that develops novel cancer immunotherapies. The company’s pipeline products include small molecule immunomodulators targeting IDO1, A2A, immune check points, STING agonist, and antibodies directed to TIGIT and Galectin 3. It also develops proprietary antibody and small molecules that aim immunosuppressive pathways. iTeos’ immunotherapies stimulate the immune system that targets tumors using a platform to identify rational combinations of immunotherapies and novel targets. The company also develops ex vivo screening assays based on different types of human samples to execute gene modulation, metabolomics library screening and expression profiling to identify novel immunosuppressive mechanisms. iTeos is headquartered in Gosselies, Belgium.

iTeos Therapeutics SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
iTeos Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
iTeos Therapeutics Raises USD75 Million in Series B Financing 10
iTeos Therapeutics Raises US$4 Million In Series A Financing 12
Partnerships 14
Cristal Therapeutics Enters into Agreement with iTeos Therapeutics 14
iTeos Therapeutics Enters into Agreement with Adimab 15
Licensing Agreements 16
iTeos Therapeutics Enters into Licensing Agreement with Pfizer 16
iTeos Therapeutics Receives Rights to IDO1 and TDO2 from Ludwig Institute for Cancer Research 17
iTeos Therapeutics SA – Key Competitors 18
iTeos Therapeutics SA – Key Employees 19
iTeos Therapeutics SA – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Jul 03, 2018: iTeos Therapeutics Names Scott Chappel As Chief Scientific Officer 21
Jun 27, 2018: iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director 22
Jun 29, 2017: iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development 23
Product News 24
11/06/2017: iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting 24
Clinical Trials 25
Feb 09, 2018: iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference 25
Feb 09, 2018: iTeos Therapeutics to Present New Preclinical Data from Anti-TIGIT Antibody Program EOS884448 at Molecular Medicine Tri-Conference 26
Jul 28, 2017: iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region 27
Apr 03, 2017: iTeos Therapeutics: iTeos Therapeutics to Present Data for Novel A2A Receptor Antagonist at American Association for Cancer Research Annual Meeting 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
iTeos Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
iTeos Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 8
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
iTeos Therapeutics Raises USD75 Million in Series B Financing 10
iTeos Therapeutics Raises US$4 Million In Series A Financing 12
Cristal Therapeutics Enters into Agreement with iTeos Therapeutics 14
iTeos Therapeutics Enters into Agreement with Adimab 15
iTeos Therapeutics Enters into Licensing Agreement with Pfizer 16
iTeos Therapeutics Receives Rights to IDO1 and TDO2 from Ludwig Institute for Cancer Research 17
iTeos Therapeutics SA, Key Competitors 18
iTeos Therapeutics SA, Key Employees 19

List of Figures
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
iTeos Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[iTeos Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C11170)販売に関する免責事項を必ずご確認ください。
★調査レポート[iTeos Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆